QGEN · Qiagen N.V.
$44.49
+2.17 (+5.13%)
At close · Aug 19
Market Cap
$8.81B
Shares
206.50M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.32
Open$43.06
Day$42.32–43.46
52W close$32.63–55.66
Avg vol 30d3.0M
Short int8.2M · 4.0% float · 4.0d
Short vol30%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+5%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
42%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−13%
trailing
YTD return
−6%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $40 › 200d $43 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +67 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.99% of float · ▲ +3.8% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
335 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
62%
expanding
EPS growth
+424%
Y/Y
Free cash flow
$453.3M
Buyback
$100.0M
authorized
Balance sheet
$815.4M
net debt
Quant / Vol
risk profile
Volatility
33%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
full year
Total net sales growth
1% – 2%
Adjusted diluted EPS
$2.43
third quarter
Total net sales growth
1% – 2%
Adjusted diluted EPS
$0.62
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Adjusted EPS
· 2025
$2.38
Net sales growth
· 2025
4% – 5%
Core portfolio sales growth
· 2025
5% – 6%
Guided vs delivered
· last 3 settled
Net sales
2023
guided at least $1.97B
$1.97B
Miss −0.2%
Adjusted EPS
2023
guided at least $2.07
$1.48
Miss −28.5%
Impact on EPS
next year
guided $0.02 – $0.03
$0.37
Beat +1380.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+5%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
42%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $40 › 200d $43 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +67 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.99% of float · ▲ +3.8% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
335 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $33
Now $42 · 42%
Range high $56
vs 200-day avg -1%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QGEN
this stock
Qiagen N.V.
|
$8.81B | -5.9% | +5.7% | — | 4.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +1.7% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +36.1% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -18.2% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QGEN | -0.8% | +4.4% | -13.0% | +2.2% | -5.9% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -0.4% | +1.9% | -23.7% | -0.5% | -18.4% |
Capital returns
Latest dividend
$0.35
/ share · ex Jul 7, 2026
Paid (TTM)
$0.35
/ share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program
· as of Jul 12, 2021
Authorized
$100.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1015820
CUSIP
N72482156
13F (30d)
330 filings
304 filers
Visit website
Investor relations